Related Experiment Video
Updated: Jul 9, 2026
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
The development of targeted therapies for hepatocellular cancer
D Chattopadhyay1, D M Manas, H L Reeves
1Northern Institute for Cancer Research, Paul 'O Gorman Building, Framlington Place, Newcastle University, Newcastle-upon-Tyne, NE2 4HH, UK.
Abstract:
Present treatment options for hepatocellular cancer (HCC) are limited to those individuals with good liver function and early stage disease. Unfortunately this includes only a minority of patients, few of which are actually cured of their cancer. Over the last 15-20 years biotechnology has made a very significant impact on medical research, to the extent that we know very much more about the regulation of normal cell growth and death, as well as the mechanisms underlying its disruption in disease processes. This knowledge has and is being rapidly exploited by academic and pharmaceutical organisations, often in collaboration. The result is the development, testing and steady introduction of therapies that target specific abnormalities in cancer cells. Although the safety and effectiveness of the majority of these agents has yet to be established in cirrhotic patients with HCC, we are hopeful that we will shortly see an increase in effective treatment options available for clinical use this disease. This review focuses on aberrant cancer proteins and pathways relevant to HCC, as well as the novel therapies or strategies targeting them, that are currently in the development or testing stages.
Insights
Novel biotechnologies are advancing hepatocellular cancer (HCC) treatments by targeting specific cancer cell abnormalities. While many new therapies are still in development, they offer hope for improved outcomes in HCC patients.
Area of Science:
- Oncology
- Biotechnology
- Hepatology
Background:
- Current hepatocellular cancer (HCC) treatments are restricted to early-stage disease and patients with good liver function.
- A minority of HCC patients benefit from existing therapies, with few achieving a complete cure.
- Biotechnology advancements have significantly improved understanding of cell growth regulation and disease mechanisms.
Purpose of the Study:
- To review novel therapies and strategies targeting aberrant cancer proteins and pathways in HCC.
- To highlight treatments currently in development or testing stages for hepatocellular cancer.
- To discuss the potential impact of emerging biotechnologies on HCC treatment.
Main Methods:
- Review of current scientific literature on HCC and emerging cancer therapies.
- Focus on aberrant cancer proteins and signaling pathways implicated in HCC development.
- Analysis of novel therapeutic agents and strategies under investigation.
Main Results:
- Identification of specific molecular targets and pathways crucial to HCC progression.
- Overview of novel therapeutic agents and strategies in preclinical and clinical development.
- Acknowledgement of the need for further safety and efficacy studies in cirrhotic HCC patients.
Conclusions:
- Emerging biotechnologies hold promise for developing targeted therapies for HCC.
- Continued research and clinical trials are essential to establish the efficacy and safety of new HCC treatments.
- An increase in effective treatment options for hepatocellular cancer is anticipated in the near future.
More Related Videos
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
07:25Development and Optimization of A Human Hepatocellular Carcinoma Patient-Derived Organoid Model for Potential Target Identification and Drug Discovery
Published on: August 18, 2023
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy